Société Arabe Des Industries Pharmaceutiques - SAIPH  was established in the year 1992 through joint Arab financing and is considered as one of the pioneering companies in Tunisia. It includes five factories for the production .SAIPH distributes its products in Tunisia and to several Arab and African Countries. It also  produces medicine with generic licenses and genetic medicine, and has developed the concept of handling for some local and international laboratories. SAIPH capital nearly amounted to TND 62 million, of which ACDIMA owns 83.495%.  For the past three years, SAIPH has been recording the best development of the pharmaceutical market in Tunisia.These encouraging results prompted SAIPH shareholders to increase their investments in order to sustain the Laboratory and give it the means to play the first roles in the Tunisian pharmaceutical industry. Much of what has been achieved, investors have decided to invest even more resources to change SAIPH’s status as a national company to that of a multinational, at the African level in an early stage. At the Tunisian level, SAIPH now has an industrial site comprising five (05) factories, manufacturing sterile forms, cephalosporins, penicillins, dry and liquid forms and soft capsules (soft gelatin) and Powders to inhale. SAIPH manufactures generic drugs, treating the major pathologies in the region, including cardiovascular drugs, antibiotics, antalgics, anti-inflammatory drugs, psychiatric drugs and also manufactures princeps for the largest multinationals.